Lycera Corporation

Merck Sharp + Dohme Corp.

Chad A Van Huis

Peter Laurence Toogood

Clarke Bentley Taylor

Thomas Daniel Aicher

Alexander Ross Hurd

Gary D Glick

William L Thomas

Kenneth Jay Barr

Vladimir Simov

Karin Ann Stein

Matthew N Mattson

Catherine M White

Blair T Lapointe

Donald James Skalitzky

Arthur Glenn Romero

Zhan Wang

Carl J Kaub

Xiao Hu

Laura Lee Celeste

Xikui Liu

Erik Krogh-Jespersen

The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR&#x3b3;) and provides adoptive cellular therapies using an agonist of ROR&#x3b3;, populations of lymphocyte cells that have been exposed to an agonist of ROR&#x3b3;, populations of dendritic cells that have been exposed to an agonist of ROR&#x3b3;, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR&#x3b3; to a patient.

Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods

The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR&#x3b3; activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.

Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

The invention provides benzenesulfonamido and related compounds, pharmaceutical compositions, methods of promoting ROR&#x3b3; activity, increasing the amount of IL-17 in a subject, and treating cancer using such benzenesulfonamido and related compounds.

Benzenesulfonamido and related compounds for use as agonists of ROR&#x3b3; and the treatment of disease

The invention provides indazole guanidine compounds that inhibit FF-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

[object Object]

Tetrahydronaphthyridine and related bicyclic compounds for inhibition of ROR&#x3b3; activity and the treatment of disease

The invention provides saturated acyl guanidine compounds that inhibit FF-ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR&#x3b3; activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.

N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ROR&#x3b3; activity and the treatment of disease

The invention provides pyridonyl guanidine compounds that inhibit FF-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

The invention provides bicyclic sulfone compounds, pharmaceutical compositions, methods of inhibiting RORy activity, reducing the amount of iL-17 in a subject, and treating immune disorders and inflammatory disorders using such bicyclic sulfone compounds. Another aspect of the invention provides a method of treating a subject suffering from a medical disorder. The method comprises administering to the subject a therapeutically effective amount of one or more bicyclic sulfone compounds described herein. In certain other embodiments, the disorder is rheumatoid arthritis.

Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease

The invention provides cycloalkyl guanidine compounds that inhibit FF-ATPase, and methods of using cyclalkyl guanidine compounds as therapeutic agents in therapy, such as treating an immune disorder, inflammatory condition, or cancer.

The invention provides pyrazolyl guanidine compounds that inhibit FF-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

Growing community of inventors

Hartland, MI, United States of America

Chad A Van Huis